Summary
27 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 106% this fiscal year.
- Out of every 100 CNY of revenue, 7.0 CNY is left as net profit.
What to watch
- Revenue fell by 18% a year over the last 3 years.
- It cut its dividend by 81% last year.
- The share price is above the Bulios Fair Price.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 33.5 CNY for 1 CNY of yearly profit. Over the last five years it was 28.2 CNY on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 33% a year over 5 years. Over the last 3 years it fell by 18% a year. For the next fiscal year analysts expect revenue to grow by 106%.
Growth in detailDoes it make money?
ReasonablyWhere 100 CNY of revenue goes
- Cost of sales 74 CNY
- Research and development 3.4 CNY
- Sales and administration 2.6 CNY
- Taxes and other 4.6 CNY
- Net profit 16 CNY
Net profit, industry median (Chemicals) 4.5 CNY
Out of every 100 CNY of revenue, 16 CNY is left as net profit.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.65%
- Paid out of profit
- 22%
You receive $0.02 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 2
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.